| Overview |
| bsm-52514r-100ul |
| p63 (51A6) Monoclonal Antibody |
| WB, FCM, IHC-P, IF(ICC), IHC |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| Human p63 between 1 to 250 amino acids |
| Monoclonal |
| 51A6 |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C for 12 months. |
| Target |
| 8626 |
| Q9H3D4 |
| Tumor protein 63, Chronic ulceRative stomatitis protein, KeRatinocyte transcription factor KET, Transformation-related protein 63, Tumor protein p73-like, p40, p51, p63, CUSP, TP63, p73L, TP63 |
| Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge. Activates transcription of the p21 promoter. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IHC-P |
1:200-400 |
| IF(ICC) |
1:50-200 |
| IHC |
|
Powered by Bioz